#

+91-9811715635

  • #
  • #
  • #
#

Global Blood Plasma Market: Size & Forecast with Impact Analysis of COVID-19 and Forecast up to 2028

Publish Date:July 2023
No. of Pages:147

Format : Adobe Reader (PDF) Instant delivery

US$ 2,250.00

Blood plasma, the liquid component of blood, plays a vital role in the field of medicine. Comprising proteins, hormones, electrolytes, and antibodies, it serves as a crucial resource for various therapeutic applications. Blood plasma holds significant medical importance due to its use in treating a wide range of conditions. Plasma-derived therapies, derived from blood plasma, have proven essential in the management of immune disorders, bleeding disorders, and rare diseases. Products such as immunoglobulins, coagulation factors, and albumin derived from plasma have saved countless lives and improved patients' quality of life. The global blood plasma market in 2022 was valued at US$35.14 billion and is expected to reach US$56.55 billion by 2028. In 2022, the global blood plasma market witnessed a supply of 54.75 million liters, while the global demand reached 72 million liters.

The blood plasma market is projected to grow at a CAGR of 8.25%, during the forecast period of 2023-2028. The rise in prevalence of life-threatening disorders such as immunodeficiency, the rise in geriatric population, and growth in adoption of blood plasma derivatives products are expected to drive the blood plasma market. Moreover, advances in plasma fractionation technologies, increasing awareness of the benefits of plasma-derived therapies, and the potential for personalized medicine contribute to the sector's positive outlook.

Market Segmentation Analysis:

By Type: The report splits the global blood plasma market into four different types: Immunoglobulin, Albumin, Coagulation Factors and Others. Immunoglobulin sector held the highest share in the market in 2022. Immunoglobulin products are derived from blood plasma and are used to treat various medical conditions, including immune deficiencies, autoimmune diseases, and certain infections. Immunoglobulin therapy is often required by older adults, as their immune systems tend to weaken with age. The expanding elderly population globally is driving the demand for immunoglobulin products. Moreover, advances in plasma fractionation techniques and the identification of new therapeutic uses for immunoglobulins have expanded the demand for these products. For example, immunoglobulins are increasingly being used in the treatment of neurological disorders like multiple sclerosis. However, there are still many patients undiagnosed, and consumption of immunoglobulins varies widely between regions, which suggests there is still room for further appealing growth.

By Application: The global blood plasma market can be divided into four segments on the basis of application: Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia and Other. Hemophilia segment is anticipated to grow at the fastest CAGR during the forecasted period. Hemophilia is a genetic bleeding disorder characterized by a deficiency in clotting factors, primarily factor VIII (hemophilia A) or factor IX (hemophilia B). Plasma-derived clotting factor concentrates are a crucial treatment for hemophilia patients. Technological advancements in the production of clotting factor concentrates, along with improved clinical management of hemophilia, have increased the demand for plasma-based therapies. Furthermore, efforts to improve access to treatment in developing countries and initiatives to raise awareness about hemophilia have resulted in a higher number of patients seeking treatment, thereby driving the demand for plasma-derived product.

By End User: The report divides the global blood plasma market into three end users: Hospitals, Clinics and Others. Hospitals are one of the major end users of blood plasma. They require blood plasma for various medical procedures, such as transfusions, surgeries, and treatments for patients with severe injuries or medical conditions. Patients with chronic diseases like hemophilia, immune deficiencies, and certain types of cancers may require regular blood plasma transfusions as a part of their treatment. The increasing prevalence of these diseases contributes to the demand for blood plasma in hospitals. With a globally aging population, the demand for blood plasma in hospitals is increasing.

By Region: According to this report, the global blood plasma market can be divided into four major regions: North America (The US, Canada and Mexico), Europe (Germany, UK, France, Italy and Rest of Europe), Asia Pacific (China, Japan, India, and Rest of Asia Pacific), and Rest of the World. The North American region has emerged as a dominant player in the blood plasma market. The North American blood plasma market is a well-established and thriving industry. With advanced healthcare infrastructure and high healthcare expenditure, the region has witnessed significant growth in plasma-derived products. The prevalence of chronic diseases such as immune disorders, bleeding disorders, and liver diseases has fueled the demand for plasma therapies. Technological advancements in plasma collection and fractionation techniques have further boosted the market.

Global Blood Plasma Market Dynamics:

Growth Drivers: The increasing demand for immunoglobulins in therapeutic treatments has emerged as a significant driving factor for the blood plasma market. Immunoglobulins, also known as antibodies, are proteins produced by the immune system to identify and neutralize harmful substances such as bacteria and viruses. They play a crucial role in fighting off infections and providing immunity. In recent years, there has been a growing recognition of the therapeutic potential of immunoglobulins in treating various medical conditions. Further, the market is expected to increase due to increasing plasma centers and plasma collection, aging population, rising prevalence of alpha-1 antitrypsin deficiency (AATD) and rising incidence of hemophilia.

Challenges: However, some challenges are impeding the growth of the market such as availability of alternatives and regulatory and safety considerations. Blood plasma is a crucial component in various medical therapies, including immunoglobulin therapy and coagulation factor replacement. However, ensuring the safety and regulatory compliance of blood plasma products has presented challenges. One major concern is the risk of transmitting infectious diseases through blood plasma. To mitigate this risk, strict regulations and testing protocols are imposed on blood plasma collection, processing, and distribution. The screening and testing processes are time-consuming and expensive, leading to higher production costs for plasma-derived products. These costs are eventually passed on to patients and healthcare systems, making these therapies less accessible and affordable.

Trends: A major trend gaining pace in blood plasma market is expansion of plasma fractionation facilities. Plasma fractionation is the process of separating plasma into its various components, including proteins, enzymes, and antibodies, for the development of therapeutic products. The expansion of plasma fractionation facilities has played a crucial role in meeting the growing demand for plasma-derived therapies. With the increasing prevalence of diseases requiring these therapies, such as immunodeficiency disorders, hemophilia, and autoimmune diseases, there is a need for larger and more efficient facilities to process plasma and produce the necessary products. The expansion of these facilities enables higher production volumes, ensuring a sufficient supply of plasma-derived therapies to meet the needs of patients worldwide. More trends in the market are believed to augment the growth of blood plasma market during the forecasted period include explosive growth of cell & gene therapies in development, increasing adoption of therapeutic plasma exchange (TPE), etc.

Impact Analysis of COVID-19 and Way Forward:

The pandemic had a positive impact on the blood plasma market. The urgency of the pandemic stimulated research and development activities related to plasma-based therapies. Pharmaceutical companies and research institutions focused on developing monoclonal antibodies, hyperimmune globulins, and other plasma-derived treatments to combat COVID-19. This accelerated R&D has the potential to impact the future of the blood plasma market beyond the pandemic. Regulatory agencies, such as the US Food and Drug Administration (FDA), implemented emergency use authorization (EUA) to facilitate the use of convalescent plasma for COVID-19 treatment. These temporary measures streamlined the approval process and allowed for more widespread use of plasma therapies.

The post-COVID era would likely see significant investment in research and development efforts related to blood plasma therapies. Companies and organizations will focus on improving manufacturing processes, optimizing the collection of convalescent plasma, and developing new treatments based on plasma-derived products.

Competitive Landscape and Recent Developments:

The blood plasma market is consolidated with the presence of few number of players dominating worldwide. Compliance with regulatory requirements can be challenging for smaller players, leading to consolidation in the market as larger companies with greater resources and infrastructure dominate.

Key players of the blood plasma market are:

CSL Limited
Takeda Pharmaceutical Company Limited
Grifols, S.A.
Baxter International Inc.
Kedrion Biopharma
ADMA Biologics, Inc.
Octapharma
LFB S.A.
Taibang Biotech Group Inc. (China Biologic Products)

Key players are establishing and expanding their plasma collection centers to ensure a consistent supply of source blood plasma, allowing them to meet the growing demand for plasma-derived therapies. Companies are engaging in strategic partnerships, collaborations, and acquisitions to enhance their product portfolios, expand their market reach, and strengthen their position in the blood plasma market. Given the regulatory scrutiny surrounding plasma-derived therapies, companies are emphasizing stringent quality control measures and safety standards to gain a competitive edge. For instance, on April 25 2022, Grifols announced the completion of the acquisition of 100% of the share capital of Tiancheng (Germany) Pharmaceutical Holdings AG, a German company that holds 89.88% of the ordinary shares and 1.08% of the preferred shares of Biotest AG, a European healthcare company specialized in innovative hematology and clinical immunology. The Biotest AG acquisition is a strategic transaction that would contribute to expanding and diversifying Grifols’ plasma supply; strengthening the company’s operations and revenues in Europe, Middle East and Africa; and supporting the company’s economic performance.

Scope of the Report

The report titled “Global Blood Plasma Market: Analysis By Demand, By Supply, By Type, By Application, By Collection Type, By End User, By Region, Size & Forecast with Impact Analysis of COVID-19 and Forecast up to 2028”, includes:

-- An in-depth analysis of the global blood plasma market by value, by demand, by supply, by type, by application, by end user, etc.

-- The regional analysis of the blood plasma market, including the following regions:

Asia Pacific (China, Japan, India, South Korea, and Rest of Asia Pacific)
North America (The US, Canada and Mexico)
Europe (Germany, UK, France, Italy, Spain and Rest of Europe)
Rest of the World

-- The comprehensive examination of the global blood plasma demand and supply, categorized by collection type.

-- Comprehensive information about emerging markets. This report analyses the market for various segments across geographies.

-- Provides an analysis of the COVID-19 impact on the global blood plasma market, with post COVID impact analysis.

-- Assesses the key opportunities in the market and outlines the factors that are and will be driving the growth of the industry. Growth of the overall blood plasma market has also been forecasted for the period 2023-2028, taking into consideration the previous growth patterns, the growth drivers, and the current and future trends.

-- Evaluation of the potential role of blood plasma to improve the market status.

-- Identification of new technological developments, R&D activities, and collaborations occurring in the blood plasma market.

-- In-depth profiling of the key players, including the assessment of the business overview, market strategies, regional and business segments of the leading players in the market.

-- The recent developments, mergers and acquisitions related to mentioned key players are provided in the market report.

-- The in-depth analysis provides an insight into the market, underlining the growth rate and opportunities offered in the business.


Tags :









1. Executive Summary

2. Introduction

2.1 Blood Plasma: An Overview 
2.1.1 Definition of Blood Plasma 

2.2 Blood Plasma Segmentation: An Overview 
2.2.1 Blood Plasma Segmentation

3. Global Market Analysis

3.1 Global Blood Plasma Market: An Analysis

3.1.1 Global Blood Plasma Market: An Overview
3.1.2 Global Blood Plasma Market by Value
3.1.3 Global Blood Plasma Market by Type (Immunoglobulin, Albumin, Coagulation Factors and Others)
3.1.4 Global Blood Plasma Market by Application (Immunodeficiency Diseases, Hypogammaglobulinemia, Hemophilia and Other)
3.1.5 Global Blood Plasma Market by End User (Hospitals, Clinics and Others)
3.1.6 Global Blood Plasma Market by Region (North America, Europe, Asia Pacific, and ROW)

3.2 Global Blood Plasma Market: Type Analysis 

3.2.1 Global Blood Plasma Market by Type: An Overview
3.2.2 Global Immunoglobulin Blood Plasma Market by Value
3.2.3 Global Albumin Blood Plasma Market by Value
3.2.4 Global Coagulation Factors Blood Plasma Market by Value
3.2.5 Global Other Blood Plasma Types Market by Value

3.3 Global Blood Plasma Market: Application Analysis 

3.3.1 Global Blood Plasma Market by Application: An Overview
3.3.2 Global Immunodeficiency Diseases Blood Plasma Market by Value
3.3.3 Global Hypogammaglobulinemia Blood Plasma Market by Value
3.3.4 Global Hemophilia Blood Plasma Market by Value
3.3.5 Global Other Blood Plasma Applications Market by Value

3.4 Global Blood Plasma Market: End User Analysis 

3.4.1 Global Blood Plasma Market by End User: An Overview
3.4.2 Global Hospitals Blood Plasma Market by Value
3.4.3 Global Clinics Blood Plasma Market by Value
3.4.4 Global Other Blood Plasma End Users Market by Value

3.5 Global Blood Plasma Market Demand & Supply: An Analysis

3.5.1 Global Blood Plasma Market by Demand & Supply: An Overview
3.5.2 Global Blood Plasma Market by Demand
3.5.3 Global Blood Plasma Market by Supply
3.5.4 Global Blood Plasma Market Supply by Collection Type (Source and Recovered)
3.5.5 Global Source and Recovered Blood Plasma Market by Supply

4. Regional Market Analysis

4.1 North America Blood Plasma Market: An Analysis

4.1.1 North America Blood Plasma Market: An Overview
4.1.2 North America Blood Plasma Market by Value
4.1.3 North America Blood Plasma Market by Region (The US, Canada and Mexico)
4.1.4 The US Blood Plasma Market by Value
4.1.5 Canada Blood Plasma Market by Value
4.1.6 Mexico Blood Plasma Market by Value

4.2 Europe Blood Plasma Market: An Analysis

4.2.1 Europe Blood Plasma Market: An Overview
4.2.2 Europe Blood Plasma Market by Value
4.2.3 Europe Blood Plasma Market by Region (Germany, France, United Kingdom, Italy and Rest of the Europe)
4.2.4 Germany Blood Plasma Market by Value
4.2.5 France Blood Plasma Market by Value
4.2.6 United Kingdom Blood Plasma Market by Value
4.2.7 Italy Blood Plasma Market by Value
4.2.8 Rest of Europe Blood Plasma Market by Value

4.3 Asia Pacific Blood Plasma Market: An Analysis

4.3.1 Asia Pacific Blood Plasma Market: An Overview
4.3.2 Asia Pacific Blood Plasma Market by Value
4.3.3 Asia Pacific Blood Plasma Market by Region (China, Japan, India, and Rest of Asia Pacific)
4.3.4 China Blood Plasma Market by Value
4.3.5 Japan Blood Plasma Market by Value
4.3.6 India Blood Plasma Market by Value
4.3.7 Rest of Asia Pacific Blood Plasma Market by Value

4.4 Rest of the World Blood Plasma Market: An Analysis

4.4.1 Rest of the World Blood Plasma Market: An Overview
4.4.2 Rest of the World Blood Plasma Market by Value

5. Impact of COVID-19

5.1 Impact of COVID-19

5.1.1 Impact of COVID-19 on Blood Plasma Market
5.1.2 Decreased Plasma Collections per Centre Due to COVID
5.1.3 Post COVID Scenario

6. Market Dynamics

6.1 Growth Drivers
6.1.1 Increasing Demand for Immunoglobulin in Therapeutic Treatments
6.1.2 Increasing Plasma Centers and Plasma Collection
6.1.3 Aging Population
6.1.4 Rising Prevalence of Alpha-1 Antitrypsin Deficiency (AATD)
6.1.5 Rising Incidence of Hemophilia

6.2 Challenges
6.2.1 Availability of Alternatives 
6.2.2 Regulatory and Safety Considerations

6.3 Market Trends
6.3.1 Explosive Growth of Cell & Gene Therapies in Development
6.3.2 Increasing Adoption of Therapeutic Plasma Exchange (TPE)
6.3.3 Expansion of Plasma Fractionation Facilities

7. Competitive Landscape

7.1 Global Blood Plasma Players by Market Share
7.2 Global Blood Plasma Market Players: Major Plasma-derived Drugs
7.3 The US Blood Plasma Market Players by Plasma Collection Centers

8. Company Profiles

8.1 CSL Limited 
8.1.1 Business Overview
8.1.2 Operating Segments
8.1.3 Business Strategies

8.2 Takeda Pharmaceutical Company Limited
8.2.1 Business Overview
8.2.2 Revenue by Therapeutic Area
8.2.3 Business Strategy

8.3 Grifols, S.A.
8.3.1 Business Overview
8.3.2 Operating Segments
8.3.3 Business Strategy

8.4 Baxter International Inc. 
8.4.1 Business Overview
8.4.2 Operating Segments
8.4.3 Business Strategies

8.5 Kedrion Biopharma
8.5.1 Business Overview
8.5.2 Operating Segments
8.5.3 Business Strategy

8.6 ADMA Biologics, Inc.
8.6.1 Business Overview
8.6.2 Operating Segments
8.6.3 Business Strategy

8.7 Octapharma 
8.7.1 Business Overview
8.7.2 Business Strategy

8.8 LFB S.A.
8.8.1 Business Overview
8.8.2 Business Strategy

8.9 Taibang Biotech Group Inc. (China Biologic Products)
8.9.1 Business Overview
Figure 1: Plasma Collection Process
Figure 2: Blood Plasma Segmentation
Figure 3: Global Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 4: Global Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 5: Global Blood Plasma Market by Type; 2022 (Percentage, %)
Figure 6: Global Blood Plasma Market by Application; 2022 (Percentage, %)
Figure 7: Global Blood Plasma Market by End User; 2022 (Percentage, %)
Figure 8: Global Blood Plasma Market by Region; 2022 (Percentage, %)
Figure 9: Global Immunoglobulin Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 10: Global Immunoglobulin Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 11: Global Albumin Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 12: Global Albumin Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 13: Global Coagulation Factors Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 14: Global Coagulation Factors Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 15: Global Other Blood Plasma Types Market by Value; 2018-2022 (US$ Billion)
Figure 16: Global Other Blood Plasma Types Market by Value; 2023-2028 (US$ Billion)
Figure 17: Global Immunodeficiency Diseases Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 18: Global Immunodeficiency Diseases Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 19: Global Hypogammaglobulinemia Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 20: Global Hypogammaglobulinemia Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 21: Global Hemophilia Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 22: Global Hemophilia Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 23: Global Other Blood Plasma Applications Market by Value; 2018-2022 (US$ Billion)
Figure 24: Global Other Blood Plasma Applications Market by Value; 2023-2028 (US$ Billion)
Figure 25: Global Hospitals Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 26: Global Hospitals Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 27: Global Clinics Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 28: Global Clinics Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 29: Global Other Blood Plasma End Users Market by Value; 2018-2022 (US$ Billion)
Figure 30: Global Other Blood Plasma End Users Market by Value; 2023-2028 (US$ Billion)
Figure 31: Global Blood Plasma Market by Demand; 2018-2022 (Million Liters)
Figure 32: Global Blood Plasma Market by Demand; 2023-2028 (Million Liters)
Figure 33: Global Blood Plasma Market by Supply; 2018-2022 (Million Liters)
Figure 34: Global Blood Plasma Market by Supply; 2023-2028 (Million Liters)
Figure 35: Global Blood Plasma Market Supply by Collection Type; 2022 (Percentage, %)
Figure 36: Global Source and Recovered Blood Plasma Market by Supply; 2018-2022 (Million Liters)
Figure 37: Global Source and Recovered Blood Plasma Market by Supply; 2023-2028 (Million Liters)
Figure 38: North America Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 39: North America Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 40: North America Blood Plasma Market by Region; 2022 (Percentage, %)
Figure 41: The US Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 42: The US Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 43: Canada Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 44: Canada Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 45: Mexico Blood Plasma Market by Value; 2018-2022 (US$ Million)
Figure 46: Mexico Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 47: Europe Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 48: Europe Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 49: Europe Blood Plasma Market by Region; 2022 (Percentage, %)
Figure 50: Germany Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 51: Germany Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 52: France Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 53: France Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 54: United Kingdom Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 55: United Kingdom Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 56: Italy Blood Plasma Market by Value; 2018-2022 (US$ Million)
Figure 57: Italy Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 58: Rest of Europe Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 59: Rest of Europe Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 60: Asia Pacific Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 61: Asia Pacific Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 62: Asia Pacific Blood Plasma Market by Region; 2022 (Percentage, %)
Figure 63: China Blood Plasma Market by Value, 2018-2022 (US$ Billion)
Figure 64: China Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 65: Japan Blood Plasma Market by Value, 2018-2022 (US$ Billion)
Figure 66: Japan Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 67: India Blood Plasma Market by Value, 2018-2022 (US$ Million)
Figure 68: India Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 69: Rest of Asia Pacific Blood Plasma Market by Value, 2018-2022 (US$ Billion)
Figure 70: Rest of Asia Pacific Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 71: Rest of the World Blood Plasma Market by Value; 2018-2022 (US$ Billion)
Figure 72: Rest of the World Blood Plasma Market by Value; 2023-2028 (US$ Billion)
Figure 73: Global Plasma Centre Collections Growth Rate, 2011-2019 & 2019-2021 (Percentage, %)
Figure 74: Global Immunoglobulin Demand (or Ig Volumes Distributed); 2016-2021 (Million Grams)
Figure 75: The US Plasma Collection Estimates; 2020-2025 (Million Liters)
Figure 76: The US Number of Plasma Centers; 2018-2021 (Units)
Figure 77: Global Percentage Of Population Aged 65 Years Or Over; 2022, 2030 & 2050 (Percentage, %)
Figure 78: The US Projected Cell Therapies Launches; 2021 & 2024 (Units)
Figure 79: The US Projected Gene Therapies Launches; 2021 & 2024 (Units)
Figure 80: Global Blood Plasma Players by Market Share; 2022 (Percentage, %)
Figure 81: The US Blood Plasma Market Players by Plasma Collection Centers; 2018-2021 (Units)
Figure 82: CSL Limited Revenue by Segments; 2022 (Percentage, %)
Figure 83: Takeda Pharmaceutical Company Limited Revenue by Therapeutic Area; 2023 (Percentage, %)
Figure 84: Grifols, S.A. Sales by Segments; 2022 (Percentage, %)
Figure 85: Baxter International Inc. Net Sales by Segments; 2022 (Percentage, %)
Figure 86: Kedrion Biopharma Revenue by Segment; 2022 (Percentage, %)
Figure 87: ADMA Biologics, Inc. Revenue by Segment; 2022 (Percentage, %)
Table 1: Global Blood Plasma Market Players: Major Plasma-derived Drugs